Eurofins Scientific Sa

to decline.

Please note that this call is being recorded and will later be available for replay on the Eurofins Investor Relations website. Throughout today's presentation, all participants will be in a listen-only mode. The presentation will be followed by a question and answer session. If you would like to ask a question, you may press star followed by one on your touchtone telephone to register for questions. For operator assistance, please press the star key followed by zero. During today's call, Eurofin's management may make forward-looking statements, including but not limited to statements and the related assumptions. Management will also discuss alternative performance measures such as organic growth and EBITDA, which are defined in the footnotes of our press releases. Actual results may differ materially from objectives discussed. Risks and uncertainties that may affect Eurofin's future results include but are not limited to those described in the risk factor section of the Eurofins annual and half-year reports. Please also read the disclaimer on page two of this presentation, subject to which this call and Q&A session are made. Let me now turn you over to Dr. Gilles Martin, Eurofins CEO. Please go ahead.

Thank you, Bernard. Hello, everybody, and thank you for joining our call. We do have a slideshow that has been put online, and you should have received it. a few pages of that slideshow. If we go to page three.